KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Operating Expenses data on record, last reported at $1.5 billion in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 193.72% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $4.1 billion, down 33.15%, while the annual FY2025 figure was $2.2 billion, 64.84% down from the prior year.
  • Other Operating Expenses reached $1.5 billion in Q4 2025 per VRTX's latest filing, up from $1.4 billion in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.8 billion in Q2 2024 and bottomed at $188.4 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $807.6 million, with a median of $414.6 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 1052.09% in 2024, then plummeted 91.48% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $1.4 billion in 2021, then tumbled by 77.35% to $307.7 million in 2022, then increased by 9.03% to $335.5 million in 2023, then soared by 51.92% to $509.7 million in 2024, then skyrocketed by 193.72% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $1.5 billion in Q4 2025, $1.4 billion in Q3 2025, and $410.6 million in Q2 2025.